002004 Stock Overview
Engages in the medicine, medical care, agrochemicals, new materials, tourism, and other businesses in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Huapont Life Sciences Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.45 |
| 52 Week High | CN¥5.23 |
| 52 Week Low | CN¥3.68 |
| Beta | 0.48 |
| 11 Month Change | 10.42% |
| 3 Month Change | 14.99% |
| 1 Year Change | -6.32% |
| 33 Year Change | -30.58% |
| 5 Year Change | -8.06% |
| Change since IPO | 159.80% |
Recent News & Updates
Shareholder Returns
| 002004 | CN Chemicals | CN Market | |
|---|---|---|---|
| 7D | -0.9% | 1.5% | 2.7% |
| 1Y | -6.3% | -7.9% | 4.6% |
Return vs Industry: 002004 exceeded the CN Chemicals industry which returned -10.8% over the past year.
Return vs Market: 002004 underperformed the CN Market which returned 0.1% over the past year.
Price Volatility
| 002004 volatility | |
|---|---|
| 002004 Average Weekly Movement | 4.6% |
| Chemicals Industry Average Movement | 7.1% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in CN Market | 11.4% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 002004 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002004's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 12,580 | Hai An Zhang | www.huapont.com.cn |
Huapont Life Sciences Co.,Ltd. engages in the medicine, medical care, agrochemicals, new materials, tourism, and other businesses in China and internationally. The company is involved in the production and sale of pharmaceutical preparations and raw materials.
Huapont Life Sciences Co.,Ltd. Fundamentals Summary
| 002004 fundamental statistics | |
|---|---|
| Market cap | CN¥8.78b |
| Earnings (TTM) | CN¥228.50m |
| Revenue (TTM) | CN¥11.65b |
38.4x
P/E Ratio0.8x
P/S RatioIs 002004 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002004 income statement (TTM) | |
|---|---|
| Revenue | CN¥11.65b |
| Cost of Revenue | CN¥7.55b |
| Gross Profit | CN¥4.10b |
| Other Expenses | CN¥3.87b |
| Earnings | CN¥228.50m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 29, 2024
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 35.22% |
| Net Profit Margin | 1.96% |
| Debt/Equity Ratio | 59.7% |
How did 002004 perform over the long term?
See historical performance and comparison